pISSN 1226-6051
eISSN 2508-786X

Table. 3.

Table. 3.

Logistic regression analysis results for problems affecting the occurrence of arthralgia or myalgia after taking bisphosphonate


Factors Odds ratio (95% CI)
Sex Female 0.31 (0.07-1.30)
Menopausal status Menopausal 0.42 (0.04-4.01)
Parity 1~2 1.00
3 0.21 (0.04-0.98)
Smoking status Non-smoking 1.00
Ex-smoking 1.74 (0.34-8.86)
Alcohol status Less than once a week 1.00
More than twice a week 0.92 (0.11-7.92)
Exercise status Less than 20 minutes, 3 times a week, 1.00
More than 20 minutes, 3 times a week 0.37 (0.14-0.98)
Medication Alendronate 1.00
Risedronate 1.24 (0.42-3.71)
Ibandronate 1.86 (0.47-7.31)
Dosing frequency Once daily 2.75 (0.46-16.63)
Once a week 0.83 (0.30-2.27)
Once a month 1.00
Start of medication Within the last 1 month 1.00
Within the last 3 months 1.33 (0.20-9.08)
Within the last 6 months 0.89 (0.13-5.89)
Within the last 1 year 1.01 (0.25-4.06)
Injection for osteoporosis treatment 1.96 (0.64-6.01)
Combined medication NSAIDs 1.83 (0.64-5.22)
Corticosteroid 1.39 (0.15-12.55)
Statin 1.06 (0.41-2.76)
DPP-4 inhibitor 1.41 (0.29-6.97)
Others 0.94 (0.34-2.60)
Comorbidity Rheumatoid arthritis 2.35 (0.23-23.77)
Osteoarthritis 0.86 (0.27-2.75)
Diabetes 0.72 (0.20-2.63)
Hyperlipidemia 1.26 (0.49-3.24)
Others 2.28 (0.86-6.07)

*The odds ratio is calculated by limiting to women among all respondents.

Abbreviation: CI, confidence interval, NSAIDs, non-steroidal anti-inflammatory drugs, DPP-4, dipeptidyl peptidase-4

Korean J Clin Pharm 2021;31:180-7 https://doi.org/10.24304/kjcp.2021.31.3.180
© 2021 Korean J Clin Pharm